Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Skin CancerMelanoma
- Interventions
- Biological: 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT02111863
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
- Conditions
- Metastatic CancerMetastatic Melanoma
- Interventions
- Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT02062359
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
- Conditions
- Metastatic MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Biological: Autologous CD8+ Melanoma Specific T CellsOther: Laboratory Biomarker Analysis
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02027935
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT01993719
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
- Conditions
- Breast CancerMeningiomaNon-Small Cell Lung CancerMelanomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01967823
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
- Conditions
- Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: NGFR-transduced Autologous T Lymphocytes
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01955460
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2
- Conditions
- Type 1 Diabetes
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2015-06-23
- Target Recruit Count
- 40
- Registration Number
- NCT01827735
- Locations
- 🇬🇧
Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge, United Kingdom
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
- Conditions
- Metastatic Ocular MelanomaMetastatic Uveal Melanoma
- Interventions
- Biological: Young Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01814046
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01754376
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
- Conditions
- Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Biological: CXCR2-transduced Autologous Tumor Infiltrating LymphocytesOther: Laboratory Biomarker AnalysisBiological: NGFR-transduced Autologous T LymphocytesOther: Quality-of-Life Assessment
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01740557
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.